Savvy Advisors Inc. Sells 15,497 Shares of Novo Nordisk A/S $NVO

Savvy Advisors Inc. trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 31.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,327 shares of the company’s stock after selling 15,497 shares during the period. Savvy Advisors Inc.’s holdings in Novo Nordisk A/S were worth $1,696,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. True Wealth Design LLC increased its position in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $25,000. American National Bank & Trust bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $28,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $30,000. Finally, Allianz SE increased its position in shares of Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after purchasing an additional 238 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 0.9%

Shares of NYSE NVO opened at $36.66 on Tuesday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm’s 50 day simple moving average is $42.88 and its two-hundred day simple moving average is $49.56. The stock has a market capitalization of $163.70 billion, a P/E ratio of 10.57, a PEG ratio of 8.75 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 50.43%.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Finally, Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.